EP2496256A4 - Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines - Google Patents

Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines

Info

Publication number
EP2496256A4
EP2496256A4 EP10828938.0A EP10828938A EP2496256A4 EP 2496256 A4 EP2496256 A4 EP 2496256A4 EP 10828938 A EP10828938 A EP 10828938A EP 2496256 A4 EP2496256 A4 EP 2496256A4
Authority
EP
European Patent Office
Prior art keywords
poxvirus
immunoconjugates
subunit
antibodies against
presenting cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10828938.0A
Other languages
German (de)
French (fr)
Other versions
EP2496256A2 (en
Inventor
Alice P Taylor
Boby Makabi-Panzu
David M Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Molecular Medicine and Immunology
Original Assignee
Center for Molecular Medicine and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed by Center for Molecular Medicine and Immunology filed Critical Center for Molecular Medicine and Immunology
Publication of EP2496256A2 publication Critical patent/EP2496256A2/en
Publication of EP2496256A4 publication Critical patent/EP2496256A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
EP10828938.0A 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines Withdrawn EP2496256A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25836909P 2009-11-05 2009-11-05
US25872909P 2009-11-06 2009-11-06
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US37805910P 2010-08-30 2010-08-30
PCT/US2010/054668 WO2011056721A2 (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines

Publications (2)

Publication Number Publication Date
EP2496256A2 EP2496256A2 (en) 2012-09-12
EP2496256A4 true EP2496256A4 (en) 2013-07-17

Family

ID=43970701

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10828938.0A Withdrawn EP2496256A4 (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines

Country Status (6)

Country Link
EP (1) EP2496256A4 (en)
CN (1) CN102573902A (en)
AU (1) AU2010315432A1 (en)
CA (1) CA2776563A1 (en)
IN (1) IN2012DN02692A (en)
WO (1) WO2011056721A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2014047124A1 (en) * 2012-09-18 2014-03-27 University Of Washington Through Its Center For Commercialization Compositions and methods for delivery of antigens to plasmacytoid dendritic cells
WO2016126611A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
JP7073258B2 (en) 2015-11-19 2022-05-23 レビトープ リミテッド Mutual complementation of functional antibody fragments for a two-component system against undesired cell redirection killing
CN109172818B (en) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 Protein vaccinia vaccine and efficacy detection method thereof
CN109187982B (en) * 2018-08-02 2021-06-04 浙江康佰裕生物科技有限公司 Method for screening and identifying TLR vaccine adjuvant
CA3117378A1 (en) * 2018-10-22 2020-04-30 Icellkealex Therapeutics Llc Mutant vaccinia viruses and use thereof
CN111474339A (en) * 2020-04-17 2020-07-31 浙江康佰裕生物科技有限公司 Method for labeling poxvirus particles by fluorescence and application thereof

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (en) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Hiv fusion polypeptide
WO1999036507A1 (en) * 1998-01-15 1999-07-22 Genitrix, Llc Vaccine compositions and methods of modulating immune responses
US20010014327A1 (en) * 1995-06-07 2001-08-16 Naveen N Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
US20020040130A1 (en) * 2000-07-10 2002-04-04 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20030198595A1 (en) * 1998-06-22 2003-10-23 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2004094613A2 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
WO2006107786A2 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US20070086942A1 (en) * 2005-10-19 2007-04-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2007046893A2 (en) * 2005-10-19 2007-04-26 Ibc Pharmaceuticals, Inc. Methods for generating bioactive assemblies and uses thereof
US20070140966A1 (en) * 2005-10-19 2007-06-21 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007075270A2 (en) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007134037A2 (en) * 2006-05-15 2007-11-22 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
WO2009055653A1 (en) * 2007-10-26 2009-04-30 Ibc Pharmaceuticals, Inc. Pegylation by the dock and lock (dnl) technique
US20090191225A1 (en) * 2005-04-06 2009-07-30 Ibc Pharmaceuticals, Inc. Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities
US20090202487A1 (en) * 2005-04-06 2009-08-13 Ibc Pharmaceuticals, Inc. Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
WO2009126558A1 (en) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395422T1 (en) * 1995-06-07 2008-05-15 Sanofi Pasteur Ltd CHIMERIC ANTIBODIES FOR DELIVERY OF ANTIGENS TO SELECTED CELLS OF THE IMMUNE SYSTEM
ATE477276T1 (en) * 2002-03-01 2010-08-15 Immunomedics Inc INTERNALIZATION OF ANTI CD74 MONOCLONAL ANTIBODIES AND THEIR USES
JP5214252B2 (en) * 2005-03-03 2013-06-19 イミューノメディクス、インコーポレイテッド Humanized L243 antibody
WO2006113927A2 (en) * 2005-04-20 2006-10-26 University Of Washington Immunogenic vaccinia peptides and methods of using same

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (en) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Hiv fusion polypeptide
US20010014327A1 (en) * 1995-06-07 2001-08-16 Naveen N Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
WO1999036507A1 (en) * 1998-01-15 1999-07-22 Genitrix, Llc Vaccine compositions and methods of modulating immune responses
US20030198595A1 (en) * 1998-06-22 2003-10-23 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US20020040130A1 (en) * 2000-07-10 2002-04-04 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2004094613A2 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
WO2006107786A2 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US20090191225A1 (en) * 2005-04-06 2009-07-30 Ibc Pharmaceuticals, Inc. Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities
US20090202487A1 (en) * 2005-04-06 2009-08-13 Ibc Pharmaceuticals, Inc. Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
US20070086942A1 (en) * 2005-10-19 2007-04-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2007046893A2 (en) * 2005-10-19 2007-04-26 Ibc Pharmaceuticals, Inc. Methods for generating bioactive assemblies and uses thereof
US20070140966A1 (en) * 2005-10-19 2007-06-21 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007075270A2 (en) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007134037A2 (en) * 2006-05-15 2007-11-22 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
WO2009055653A1 (en) * 2007-10-26 2009-04-30 Ibc Pharmaceuticals, Inc. Pegylation by the dock and lock (dnl) technique
WO2009126558A1 (en) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. M. GOLDENBERG ET AL: "Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting", THE JOURNAL OF NUCLEAR MEDICINE, vol. 49, no. 1, 1 January 2008 (2008-01-01), pages 158 - 163, XP055028152, ISSN: 0161-5505, DOI: 10.2967/jnumed.107.046185 *
See also references of WO2011056721A2 *

Also Published As

Publication number Publication date
EP2496256A2 (en) 2012-09-12
AU2010315432A1 (en) 2012-04-12
WO2011056721A2 (en) 2011-05-12
CN102573902A (en) 2012-07-11
WO2011056721A3 (en) 2011-10-13
CA2776563A1 (en) 2011-05-12
IN2012DN02692A (en) 2015-09-04

Similar Documents

Publication Publication Date Title
EP2496256A4 (en) Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
EP2406290A4 (en) Antigen presenting cell targeted cancer vaccines
HK1245334A1 (en) Improved vaccines for human papilloma virus and methods for using the same
IL209967A0 (en) Cdca1 epitope peptides and vaccines containing the same
IL229926A (en) Neil3 peptides and vaccines including the same
IL214435A0 (en) Foxm1 peptides and vaccines containing the same
IL219976A0 (en) Imp-3 oligopeptides and vaccines including the same
EP2491946A4 (en) Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof
IL214211A0 (en) Stable vaccine compositions and methods for preparing the same
EP2460878A4 (en) Orf7 deficient varicella virus, vaccine comprising the virus and use thereof
ZA201303886B (en) Tomm34 peptides and vaccines including the same
IL216211A0 (en) Cdc45l peptides and vaccines including the same
IL213318A0 (en) C1orf59 peptides and vaccines including the same
EP2430039A4 (en) Ttk peptides and vaccines including the same
IL220146A0 (en) Tmem22 peptides and vaccines including the same
IL215268A0 (en) C6orf167 peptides and vaccines containing the same
IL221474A0 (en) Hjurp peptides and vaccines including the same
EP2614146A4 (en) Ttll4 peptides and vaccines containing the same
IL225552A0 (en) Wdhd1 peptides and vaccines including the same
IL225553A0 (en) C180rf54 peptides and vaccines including the same
ZA201104890B (en) Wdrpuh epitope peptides and vaccines containing the same
EP2453916A4 (en) Supralingual vaccines and applicators

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120601

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130619

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/56 20060101ALI20130613BHEP

Ipc: C07K 16/28 20060101ALI20130613BHEP

Ipc: A61K 47/48 20060101ALI20130613BHEP

Ipc: C07K 14/52 20060101ALI20130613BHEP

Ipc: A61P 35/00 20060101ALI20130613BHEP

Ipc: C07K 16/46 20060101AFI20130613BHEP

Ipc: C07K 16/24 20060101ALI20130613BHEP

Ipc: C07K 16/30 20060101ALI20130613BHEP

Ipc: C07K 16/44 20060101ALI20130613BHEP

Ipc: A61K 39/395 20060101ALI20130613BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20150401